Whitehawk Therapeutics Inc
WHWKAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.20 | $-0.30 | — | -$350.0K |
| May 7, 2026 | $-0.32 | $-0.36 | — | — |
| Mar 12, 2026 | $-0.34 | $-0.55 | — | — |
| Nov 6, 2025 | $-0.26 | $-0.51 | — | $25.0M |
| Aug 7, 2025 | $-0.76 | $0.49 | — | $50.0M |
| May 8, 2025 | $1.83 | $-0.46 | $7.1M | $50.0M |
| Mar 18, 2025 | $-0.67 | $-0.29 | $7.2M | $7.4M |
| Nov 6, 2024 | $-0.46 | $-0.46 | $7.2M | $6.6M |
News
Surrozen (NASDAQ: SRZN - Get Free Report) and Whitehawk Therapeutics (NASDAQ: WHWK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation. Volatility and Risk Surrozen has a beta of
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price target among
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's Next-Generation MUC16-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Oct. 1, 2026 /PRNewswi…
Shares of Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026PR Newswire
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently devel…
Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective Sept…
MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences: Cantor Global Healthcare Conference 2026 – management will participate in investor meetings on September 9, 2026.
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.
The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.